In celebration of Clinical Trials Day 2026, we have created a masterclass about medical monitoring. This is the second blog of the series, we take a look at medical monitoring from a biotech perspective – why it is especially important and what can you do to protect your assets?

The Biotech Challenge

For a biotech, a clinical trial is rarely just a scientific endeavour. It is a strategic asset that will be scrutinised by regulators, evaluated by potential partners, and presented to investors as evidence that your molecule is worth backing. The stakes are high, the resources are often stretched, and the margin for error is slim.

In this context, medical monitoring is one of the most important (and most frequently underinvested) activities in clinical development. In this blog, we explain why biotechs should treat medical monitoring as a core programme investment, not an afterthought.

What Can Go Wrong Without It

Without experienced medical oversight, problems in trial data can go undetected until they become expensive. A pattern of laboratory abnormalities that individually appear unremarkable may collectively signal a toxicity concern. An adverse event coded incorrectly at a site may distort the safety profile. A protocol deviation that affects eligibility may undermine the reliability of efficacy data.

For a biotech running a small-to-mid-size trial, any one of these issues, if caught late, can delay a programme, trigger regulatory queries, or, in the worst case, compromise the validity of the dataset that your entire development strategy depends upon.

Quality by Design: Now a Regulatory Requirement

The ICH E6(R3) guidelines, which took effect in the UK on 28th April 2026, formalise what experienced clinical teams have long known: quality must be built into a trial from the very beginning. For biotechs, this means engaging medical monitoring expertise at the protocol design stage.

A skilled medical monitor can contribute to risk identification during protocol development, advise on the safety data review schedule, and ensure that monitoring plans are proportionate to the risks of your specific molecule and patient population. This is precisely the kind of expert, proactive support that Pharmora provides.

Protecting the Asset

Your clinical programme is your most valuable asset. The integrity of your safety and efficacy data, the quality of your adverse event reporting, and the credibility of your clinical team’s oversight are all factors that sophisticated investors, licensing partners, and regulators will scrutinise.

Engaging a specialist service provider like Pharmora to lead medical monitoring demonstrates to those stakeholders that safety is being managed by experts – people whose entire professional focus is the systematic review and interpretation of clinical trial data. Unlike large CROs where medical monitoring may be one of dozens of services delivered by generalist teams, at Pharmora it is central to our identity and our expertise.

Start Early, Spend Wisely

One of the most common (and most costly) mistakes in clinical development is treating medical monitoring as a late-stage activity. The truth is that the earlier expert monitoring is engaged, the more value it delivers. Early identification of a safety signal can inform a protocol amendment that protects participants and preserves the dataset. Late identification of the same signal may require a study halt, a regulatory notification, and months of remediation. Pharmora has supported clients with insufficient resources to review multiple urgent signals, and can use these skills to save a clinical trial from an unnecessary hold.

There are countless examples of clinical trials where money was “saved” by cutting back on medical monitoring, but ultimately the trial failed due to poor quality data.

Pharmora works with biotechs at every stage of development, from first-in-human studies to pivotal trials. We offer flexible, expert-led medical monitoring that scales to the size and complexity of your programme, without the overhead of a large CRO.

In case you missed a previous instalment, or are looking to read the rest of this exciting masterclass, click the links below to navigate through the series:
1 – What is it and why does it matter?
3 – Medical Monitoring and the Investor Perspective
4 – Medical Monitoring in Biosimilar Development
5 –  Medical Monitoring in Generics Development

To find out how Pharmora can support your programme, contact us at info@pharmora.com or visit www.pharmora.com.